Overview


According to FutureWise analysis the market for antidepressant drugs in 2023 is US$ 17.21 billion, and is expected to reach US$ 22.18 billion by 2031 at a CAGR of 3.20%.

Antidepressants are common prescription medications that help relieve the symptoms of depression and anxiety. Depression is a mood disorder described as constant feelings of sadness and a loss of interest in things and activities. It can also lead to difficulty in thinking, memory, motivation, eating, and other daily exercises. There are several types of antidepressants. Different antidepressants cause different side effects, but common side effects include nausea, dizziness, weight gain, and sexual problems. Most individuals need to take antidepressants for at least 6 to 12 months, but many individuals take them for much longer. In addition, most antidepressants help relieve depression by impacting the neurotransmitters, also called chemical messengers, which help in communication between brain cells. 

There are several types (classes) of antidepressants, including serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, and others. SSRIs antidepressants generally cause fewer bothersome side effects and are less likely to cause issues at higher therapeutic doses than other antidepressants. Healthcare professionals often start treatment by prescribing selective serotonin reuptake inhibitors. SSRIs include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil, Pexeva), citalopram (Celexa), and escitalopram (Lexapro). Also, Tricyclic antidepressants, such as imipramine, nortriptyline (Pamelor), amitriptyline, doxepin, and desipramine (Norpramin), tend to cause more side effects than newer antidepressants. So tricyclic antidepressants typically aren't prescribed unless tried other antidepressants first without progress.

FutureWise Market Research has published a report that provides an insightful analysis antidepressant drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, antidepressant drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Alkermes Plc
  • Allergan Plc
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • H. Lundbeck
  • MerckCo., Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Antidepressant Drugs Market:

  • In March 2021, the FDA granted approval for a new indication for the antidepressant drug Vraylar (cariprazine), which is marketed by Allergan (now part of AbbVie Inc.). Vraylar is now approved for treating depressive attacks associated with bipolar I disorder in adults.

  • In January 2021, Janssen Pharmaceuticals, Inc. announced that the U.S. FDA had approved its antidepressant drug, Spravato (esketamine), to treat depressive symptoms in adults with significant depressive disorder who have not responded to other treatments. This approval marked an important development in depression treatment, as Spravato is the first medication in decades to use a new mechanism of action for treating depression.

The increasing prevalence of depression associated with mental health disorders globally is a significant driver for the antidepressant drugs market. This surge might be attributed to various factors, including raising levels of stress in modern society, shifts in lifestyle patterns, and enduring societal pressures. As these challenges become increasingly crucial, the demand for efficacious antidepressant drugs continues to increase, further propelling the market expansion. Furthermore, the rise in collaborations and partnerships among various industries and companies is expected to boost the growth of the antidepressant market over the forecast period. This synergy produces a productive environment for innovation, allowing the development of novel treatment strategies and the introduction of advanced technologies. Also, such partnerships enable the pooling of resources, expertise, and market understandings, thus enhancing the efficiency of research and distribution networks. For instance, in February 2021, Ginger, a company providing on-demand mental healthcare, announced a partnership agreement with Capsule, an online pharmacy. This partnership aimed to provide Ginger members with mental health drugs, including antidepressants, at home. However, the possible side effects of many antidepressant drugs, such as agitation, shakiness, anxiety, indigestion, stomach aches, diarrhea, or constipation, may pose significant restraints on market growth. These concerns regarding safety and the probability of adverse effects may act as barriers for individuals considering the initiation or continuation of antidepressant treatment, leading to seeking alternative therapeutic approaches, therefore hindering the target market.

By Depression Disorder

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

By Product

  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-norepinephrine reuptake Inhibitors
  • Monoamine oxidase Inhibitors
  • Serotonin antagonists and reuptake inhibitors
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is primarily driven by an increase in the prevalence of depression, a rise in awareness regarding depression, increasing levels of excitatory neurotransmitters or nerve cell chemicals, and advancements in R&D activities in the United States, which are expected to propel the market over the forecast period. For instance, according to the WHO, in 2021, stated that around 5% of adults are diagnosed with depression. Antidepressant drugs work by maintaining the balance of various hormones and chemicals in the brain. Moreover, the rise in the geriatric population, higher adoption of antidepressant drugs, technological development in the pharmaceutical industry, presence of major players, and increase in number of approvals for antidepressant drugs further drive growth of the market in the area.


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antidepressant Drugs Market By Depression Disorder, By Product and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antidepressant Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antidepressant Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antidepressant Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antidepressant Drugs Market, By Depression Disorder Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Major Depressive Disorder
        2. Obsessive-Compulsive Disorder
        3. Generalized Anxiety Disorder
        4. Panic Disorder
        5. Others

  • 8.   Antidepressant Drugs Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tricyclic Antidepressants
        2. Selective Serotonin Reuptake Inhibitors
        3. Serotonin-norepinephrine reuptake Inhibitors
        4. Monoamine oxidase Inhibitors
        5. Serotonin antagonist and reuptake inhibitors
        6. Others

  • 9.   North America Antidepressant Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antidepressant Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antidepressant Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antidepressant Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Alkermes Plc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Allergan Plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol Myers Squibb Co.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Eli Lilly and Co.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline Plc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. H. Lundbeck
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. MerckCo., Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
           8. Pfizer Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Teva Pharmaceutical Industries Ltd.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Takeda Pharmaceutical Co. Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients